B. Braun's dedicated national sales force to
promote Rockwell Medical's hemodialysis concentrates products to
dialysis clinics across the United States
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced that the Company entered into
a three-year co-promotion services agreement with B. Braun Medical
Inc. ("B. Braun"), a leader in renal therapies including
innovative, high-quality products for hemodialysis.
As part of the agreement, Rockwell Medical designates B. Braun
as an independent, non-exclusive representative to promote the
Company's hemodialysis concentrates products to dialysis providers
in the United States, concertedly on the west coast. All terms of
the sale of any Rockwell Medical product, including price, delivery
schedule, and terms and conditions, are set by Rockwell Medical, at
the Company's sole discretion. All orders will be directed to, and
processed by, Rockwell Medical. B. Braun will receive a fee for any
sales generated by its promotional efforts.
"This co-marketing and sales arrangement with B. Braun
represents a significant commercial opportunity for Rockwell
Medical that immediately connects us to a new customer base we
wouldn't be able to reach otherwise," said Tim Chole, Senior Vice
President, Sales and Marketing at Rockwell Medical. "We are excited
to collaborate with B. Braun to augment our commercial efforts. B.
Braun’s national sales organization will enable us to generate new
business leads and integrate our hemodialysis concentrates products
into B. Braun's robust portfolio of renal care products. Now, B.
Braun's sales team will be able to introduce Rockwell Medical's
complementary products to new customers as part of a complete
portfolio, ultimately providing a positive impact on the lives of
more hemodialysis patients."
“We are pleased to align with Rockwell Medical to promote their
hemodialysis concentrate products,” said Jonathan Stapley, Senior
Director of Marketing, Active Devices at B. Braun. “This ensures we
can supply our providers and the patients they serve with a broader
range of high-quality hemodialysis products.”
About B. Braun Medical Inc.
B. Braun Medical Inc. ("B. Braun") is a leader in smart infusion
therapy and safe and effective pharmacy products, patient and
provider safety, and sustainable health solutions. Our purpose is
to help providers constantly improve patient satisfaction and
outcomes. With products and services created to help healthcare
professionals focus on what matters most—their patients—we’re
uniquely positioned to help health systems succeed now and in the
future. B. Braun is headquartered in Bethlehem, Pennsylvania and is
part of the B. Braun Group of Companies in the U.S., which includes
B. Braun Interventional Systems, Aesculap® and CAPS®. The company
employs 8,500 people at over 30 locations across North America.
Globally, the B. Braun Group of Companies employs more than 64,000
employees in 64 countries. Guided by its Sharing Expertise®
philosophy, B. Braun continuously exchanges knowledge with
customers, partners and clinicians to address the critical issues
of improving care and lowering costs. To learn more about B. Braun
Medical, explore our website.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company
that develops, manufactures, commercializes, and distributes a
portfolio of hemodialysis products for dialysis providers
worldwide. Rockwell Medical's mission is to provide dialysis
clinics and the patients they serve with the highest quality
products supported by the best customer service in the industry.
Rockwell Medical is focused on innovative, long-term growth
strategies that enhance its products, its processes, and its
people, enabling the Company to deliver exceptional value to the
healthcare system and provide a positive impact on the lives of
hemodialysis patients. Hemodialysis is the most common form of
end-stage kidney disease treatment and is usually performed at
freestanding outpatient dialysis centers, at hospital-based
outpatient centers, at skilled nursing facilities, or in a
patient’s home. Rockwell Medical's products are vital to vulnerable
patients with end-stage kidney disease, and the Company is
relentless in providing unmatched reliability and customer service.
Rockwell Medical is the second largest supplier of acid and
bicarbonate concentrates for dialysis patients in the United States
and has the vision of becoming the leading global supplier of
hemodialysis concentrates. Certified as a Great Place to Work® in
2023, Rockwell Medical is Driven to Deliver Life-Sustaining
Dialysis SolutionsTM. For more information, visit
www.RockwellMed.com.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident," “are determined,” “are on track,” “are resolute in our
vision,” "work to," "drive towards," or the negative of these
terms, and similar expressions, or statements regarding intent,
belief, or current expectations, are forward looking statements.
There can be no assurance that the collaboration will generate new
business leads or result in additional sales. While Rockwell
Medical believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Rockwell Medical's SEC filings), many of which are beyond
our control and subject to change. Actual results could be
materially different. Risks and uncertainties include, but are not
limited to those risks more fully discussed in the "Risk Factors"
section of our Annual Report on Form 10-K for the year ended
December 31, 2022, as such description may be amended or updated in
any future reports we file with the SEC. Rockwell Medical expressly
disclaims any obligation to update our forward-looking statements,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230629414033/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2024 to May 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From May 2023 to May 2024